Abstract:Background: It is suggested that neuroinflammation, in which activated microglial cells play a relevant role, contributes to the development of Parkinson's disease (PD). Consequently, the modulation of microglial activation is a potential therapeutic target to be taken into account to act against the dopaminergic neurodegeneration occurring in this neurological disorder. Several soluble and membrane-associated inhibitory mechanisms contribute to maintaining microglial cells in a quiescent/surveillant phenotype in physiological conditions. However, the presence of activated microglial cells in the brain in PD patients suggests that these mechanisms have been somehow overloaded. We focused our interest on one of the membrane-associated mechanisms, the CD200-CD200R1 ligand-receptor pair. Methods: The acute MPTP experimental mouse model of PD was used to study the temporal pattern of mRNA expression of CD200 and CD200R1 in the context of MPTP-induced dopaminergic neurodegeneration and neuroinflammation. Dopaminergic damage was assessed by tyrosine hydroxylase (TH) immunoreactivity, and neuroinflammation was evaluated by the mRNA expression of inflammatory markers and IBA1 and GFAP immunohistochemistry. The effect of the modulation of the CD200-CD200R1 system on MPTP-induced damage was determined by using a CD200R1 agonist or CD200 KO mice. Results: MPTP administration resulted in a progressive decrease in TH-positive fibres in the striatum and TH-positive neurons in the substantia nigra pars compacta, which were accompanied by transient astrogliosis, microgliosis and expression of pro- and anti-inflammatory markers. CD200 mRNA levels rapidly decreased in the ventral midbrain after MPTP treatment, while a transient decrease of CD200R1 mRNA expression was repeatedly observed in this brain area at earlier and later phases. By contrast, a transient increase in CD200R1 expression was observed in striatum. The administration of a CD200R1 agonist resulted in the inhibition of MPTP-induced dopaminergic neurodegeneration, while microglial cells showed signs of earlier activation in CD200-deficient mice. Conclusions: Collectively, these findings provide evidence for a correlation between CD200-CD200R1 alterations, glial activation and neuronal loss. CD200R1 stimulation reduces MPTP-induced loss of dopaminergic neurons, and CD200 deficiency results in earlier microglial activation, suggesting that the potentiation of CD200R1 signalling is a possible approach to controlling neuroinflammation and neuronal death in PD.

CD200R/Foxp3-mediated Signalling Regulates Microglial Activation

TLR4-TAK1-p38 MAPK pathway and HDAC6 regulate the expression of sigma-1 receptors in rat primary cultured microglia

CD200–CD200R Regulation of Microglia Activation in the Pathogenesis of Parkinson’s Disease

Expression of OX40 Ligand in Microglia Activated by IFN-γ Sustains a Protective CD4+ T-cell Response in Vitro

CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease

Microglial expression of CD83 governs cellular activation and restrains neuroinflammation in experimental autoimmune encephalomyelitis

Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model

Ecto-5′-nucleotidase (CD73) Attenuates Inflammation after Spinal Cord Injury by Promoting Macrophages/microglia M2 Polarization in Mice

Microglial Activation Mediates Host Neuronal Survival Induced by Neural Stem Cells

Triggering Receptor Expressed On Myeloid Cells 2, A Novel Regulator Of Immunocyte Phenotypes, Confers Neuroprotection By Relieving Neuroinflammation

Polymorphic regulation of mitochondrial fission and fusion modifies phenotypes of microglia in neuroinflammation

Microglia-induced Autophagic Death of Neurons Via IL-6/STAT3/miR-30d Signaling Following Hypoxia/ischemia.

Regulation of IFN-Is by MEF2D Promotes Inflammatory Homeostasis in Microglia

Identification of the Transcription Factors of CD200R1 and Its Potential Roles in Parkinson’s Disease

The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease

Programmed Death Ligand-1 on Microglia Regulates Thl Differentiation Via Nitric Oxide in Experimental Autoimmune Encephalomyelitis

Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ

Microglial MAC1 Receptor and PI3K Are Essential in Mediating Β-Amyloid Peptide-Induced Microglial Activation and Subsequent Neurotoxicity

CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke

Microglial priming by IFN-γ involves STAT1-mediated activation of the NLRP3 inflammasome

Effective inhibition of miR‐330/SHIP1/NF‐κB signaling pathway via miR‐330 sponge repolarizes microglia differentiation